CN109310761A - C-raf抑制剂的治疗用途 - Google Patents

C-raf抑制剂的治疗用途 Download PDF

Info

Publication number
CN109310761A
CN109310761A CN201780035192.1A CN201780035192A CN109310761A CN 109310761 A CN109310761 A CN 109310761A CN 201780035192 A CN201780035192 A CN 201780035192A CN 109310761 A CN109310761 A CN 109310761A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
pharmaceutical composition
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780035192.1A
Other languages
English (en)
Chinese (zh)
Inventor
G·卡波尼格罗
V·库克
A·H·迈斯
H·诺维莱尔茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN109310761A publication Critical patent/CN109310761A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780035192.1A 2016-06-10 2017-06-08 C-raf抑制剂的治疗用途 Pending CN109310761A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348720P 2016-06-10 2016-06-10
US62/348,720 2016-06-10
PCT/IB2017/053405 WO2017212442A1 (en) 2016-06-10 2017-06-08 Therapeutic uses of a c-raf inhibitor

Publications (1)

Publication Number Publication Date
CN109310761A true CN109310761A (zh) 2019-02-05

Family

ID=59215827

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780035192.1A Pending CN109310761A (zh) 2016-06-10 2017-06-08 C-raf抑制剂的治疗用途

Country Status (13)

Country Link
US (1) US20190175609A1 (enExample)
EP (1) EP3468595A1 (enExample)
JP (1) JP2019517549A (enExample)
KR (1) KR20190017767A (enExample)
CN (1) CN109310761A (enExample)
AU (1) AU2017279046B2 (enExample)
BR (1) BR112018075371A2 (enExample)
CA (1) CA3026876A1 (enExample)
CL (1) CL2018003530A1 (enExample)
IL (1) IL262961A (enExample)
MX (1) MX2018015353A (enExample)
RU (1) RU2018146886A (enExample)
WO (1) WO2017212442A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021110141A1 (zh) * 2019-12-06 2021-06-10 南京明德新药研发有限公司 Pan-RAF激酶抑制剂的联芳基化合物
CN113912591A (zh) * 2020-07-08 2022-01-11 南京明德新药研发有限公司 联芳基化合物
WO2022253334A1 (zh) * 2021-06-04 2022-12-08 南京明德新药研发有限公司 一种raf激酶抑制剂的晶型及其制备方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051306A1 (en) * 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
KR20240032157A (ko) 2017-05-02 2024-03-08 노파르티스 아게 병용 요법
WO2020185516A1 (en) 2019-03-08 2020-09-17 Auris Health, Inc. Tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and
MX2021013817A (es) 2019-05-13 2021-12-14 Novartis Ag Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
EP4048259A4 (en) 2019-10-24 2023-08-02 Kinnate Biopharma Inc. Inhibitors of raf kinases
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252977A1 (en) * 2012-03-07 2013-09-26 Deciphera Pharmaceuticals, Llc Raf Inhibitor Compounds
WO2014151616A1 (en) * 2013-03-14 2014-09-25 Novartis Ag Biaryl amide compounds as kinase inhibitors
US20150203579A1 (en) * 2014-01-23 2015-07-23 Regeneron Pharmaceuticals, Inc. Human Antibodies to PD-1
WO2015112900A1 (en) * 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof
WO2016011160A1 (en) * 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
CN105960415A (zh) * 2014-02-04 2016-09-21 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252977A1 (en) * 2012-03-07 2013-09-26 Deciphera Pharmaceuticals, Llc Raf Inhibitor Compounds
WO2014151616A1 (en) * 2013-03-14 2014-09-25 Novartis Ag Biaryl amide compounds as kinase inhibitors
US20150203579A1 (en) * 2014-01-23 2015-07-23 Regeneron Pharmaceuticals, Inc. Human Antibodies to PD-1
WO2015112900A1 (en) * 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof
CN105960415A (zh) * 2014-02-04 2016-09-21 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合
WO2016011160A1 (en) * 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAIYER A. RIZVI ET AL.: ""Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer"", 《SCIENCE》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021110141A1 (zh) * 2019-12-06 2021-06-10 南京明德新药研发有限公司 Pan-RAF激酶抑制剂的联芳基化合物
CN113912591A (zh) * 2020-07-08 2022-01-11 南京明德新药研发有限公司 联芳基化合物
CN113912591B (zh) * 2020-07-08 2023-10-20 齐鲁制药有限公司 联芳基化合物
WO2022253334A1 (zh) * 2021-06-04 2022-12-08 南京明德新药研发有限公司 一种raf激酶抑制剂的晶型及其制备方法

Also Published As

Publication number Publication date
AU2017279046A1 (en) 2018-12-06
US20190175609A1 (en) 2019-06-13
EP3468595A1 (en) 2019-04-17
CA3026876A1 (en) 2017-12-14
JP2019517549A (ja) 2019-06-24
IL262961A (en) 2018-12-31
WO2017212442A1 (en) 2017-12-14
CL2018003530A1 (es) 2019-02-15
MX2018015353A (es) 2019-09-09
KR20190017767A (ko) 2019-02-20
BR112018075371A2 (pt) 2019-03-19
AU2017279046B2 (en) 2020-07-02
RU2018146886A (ru) 2020-07-10
RU2018146886A3 (enExample) 2020-10-15

Similar Documents

Publication Publication Date Title
CN109310761A (zh) C-raf抑制剂的治疗用途
AU2021221560B2 (en) Use of glutamate modulating agents with immunotherapies to treat cancer
AU2018206481B2 (en) Methods of treating cancer with anti-PD-1 antibodies
TWI821748B (zh) 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
AU2016298823A1 (en) Combination of PD-1 antagonist with an EGFR inhibitor
JP2017535528A (ja) 組み合わせ治療
CN115768525A (zh) 用于治疗癌症的组合物和方法
WO2020211804A1 (zh) 抗pd-1抗体在制备治疗实体瘤的药物中的用途
TW201945001A (zh) 藥物組合
US20210324081A1 (en) Dosing
WO2021046293A1 (en) Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
AU2023334278A1 (en) Methods for treating cancer using anti-ctla4 antibodies
TW202446792A (zh) 使用可活化抗ｃｔｌａ４抗體與ｐｅｍｂｒｏｌｉｚｕｍａｂ組合治療癌症之方法
CN120529917A (zh) 使用抗CTLA4抗体与Pembrolizumab组合治疗癌症的方法
JP2023538683A (ja) 鼻咽頭癌の治療における抗ｐｄ－１抗体の使用
HK40006436A (en) Use of glutamate modulating agents with immunotherapies to treat cancer
HK40006436B (en) Use of glutamate modulating agents with immunotherapies to treat cancer
BR112018073781B1 (pt) Composição farmacêutica compreendendo agentes anticâncer imunoterapêutico e de modulação de glutamato, kit e uso para o tratamento de câncer
EA049786B1 (ru) Использование глутамат-модулирующих средств вместе с иммунотерапией для лечения рака

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190205

WD01 Invention patent application deemed withdrawn after publication